Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05457283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05457283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Recruiting
Start date
November 8, 2022
Completion date
August 31, 2028
Enrollment
100 (estimated)
Sites
151

Conditions

As the registry lists them; a condition with its own page is linked.

children, chronic kidney disease, proteinuria